Dynamic monitoring risk of anti-hepatoma new drug development / 中国中药杂志
China Journal of Chinese Materia Medica
;
(24): 4050-4053, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-310943
ABSTRACT
Risk monitoring of new Chinese patent anti-hepatoma drugs is tracking recognized risks and residual risks, identifying emerging risk and ensure the implementation of the plan, estimating the process of reducing effectiveness. The paper is mainly through understanding the status of Chinese patent anti-hepatoma drugs, the content, characteristic and analysis method of dynamic risk monitoring, and then select the risk control indicators, collect risk information. Finally, puts forward the thought of anti-hepatoma drugs listed evaluation in our country, and try to establish the model of dynamic risk management of anti-hepatoma drugs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Product Surveillance, Postmarketing
/
Drugs, Chinese Herbal
/
Carcinoma, Hepatocellular
/
Therapeutic Uses
/
Drug and Narcotic Control
/
Drug Therapy
/
Economics
/
Drug Discovery
/
Liver Neoplasms
/
Antineoplastic Agents, Phytogenic
Type of study:
Etiology study
/
Health economic evaluation
/
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
China Journal of Chinese Materia Medica
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS